Brief Reports
Copyright ©The Author(s) 2005. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2005; 11(36): 5696-5700
Published online Sep 28, 2005. doi: 10.3748/wjg.v11.i36.5696
p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy
Fumiko Sunada, Masayuki Itabashi, Hisanao Ohkura, Toshiyuki Okumura
Fumiko Sunada, Masayuki Itabashi, Hisanao Ohkura, Toshiyuki Okumura, Departments of Internal Medicine, Pathology, Radiology, Ibaraki Prefectural Central Hospital and Cancer Center, Koibuchi 6528, Tomobe-machi Nishiibaraki-gun, Ibaraki-ken, Japan
Author contributions: All authors contributed equally to the work.
Correspondence to: Fumiko Sunada, MD, Department of Internal Medicine, Jichi Medical School Hospital, Yakushiji 3311, Minamikawachi-machi, Kawachi-gun, Tochigi 329-0498, Japan. f-sunada@jichi.ac.jp
Telephone: +81-285-587348 Fax: +81-285-448297
Received: December 15, 2004
Revised: January 23, 2005
Accepted: January 26, 2005
Published online: September 28, 2005
Abstract

AIM: Esophageal squamous cell carcinoma is generally sensitive to chemoradiotherapy (CRT), but some cases are not. Using a retrospective analysis, we aimed to identify the predictors of the response by esophageal squamous cell carcinoma to definitive CRT.

METHODS: The intensities of expression of p53, Ki67, Bcl-2, Bax, cyclin D1, VEGF, CDC25B, and metallothionein (MT) were evaluated immunohistochemically in the biopsy specimens obtained before CRT, and the intensities of their expression were tested for correlations with the clinical effects of CRT.

RESULTS: The esophageal squamous cell carcinomas with negative p53, positive CDC25B, and negative MT expression were found to be significantly more sensitive to CRT. In addition, p53 positivity and CDC25B positivity respond well to CRT.

CONCLUSION: Esophageal squamous cell carcinomas with negative p53,positive CDC25B, and negative MT expressions respond well to CRT. Even with p53 positivity, if with CDC25B positivity, CRT can be expected.

Keywords: p53; CDC25B; Metallothionein; Chemoradiotherapy; Esophageal squamous cell carcinomas